SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer

Eur Urol. 2023 Dec;84(6):545-546. doi: 10.1016/j.eururo.2023.09.013. Epub 2023 Oct 4.

Authors

Girish S Kulkarni¹, Marian S Wettstein²

Affiliations

¹ Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. Electronic address: girish.kulkarni@uhn.ca.
² Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

PMID: 37802681
DOI: 10.1016/j.eururo.2023.09.013

No abstract available

Publication types

Editorial

MeSH terms

Adjuvants, Immunologic / therapeutic use
Administration, Intravesical
BCG Vaccine / therapeutic use
Humans
Immune Checkpoint Inhibitors / therapeutic use
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Non-Muscle Invasive Bladder Neoplasms*
Urinary Bladder Neoplasms* / drug therapy

Substances

BCG Vaccine
Immune Checkpoint Inhibitors
Adjuvants, Immunologic